Crispr Therapeutics AG (CRSP) intrinsic value & 10-year financials
Crispr Therapeutics AG (CRSP) has a Graham intrinsic value of $0.41 per share. At $49.25 on Oct 17, 2026, the stock trades 11912% above that value. Over the last 10 fiscal years revenue shrank 4.2% a year to $3.5M, with an average return on invested capital of -19.9%.
- Graham intrinsic value
- $0.41
- Share price (Oct 17, 2026)
- $49.25
- Price vs Graham value
- 11912% above
- Market cap
- $4.4B
- Revenue (FY2025)
- $3.5M
- Revenue growth (10-yr CAGR)
- -4.2%
- ROIC (10-yr avg)
- -19.9%
- Free cash flow (FY2025)
- -$345.9M
CRSP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.5M | -$581.6M | -$6.47 | -$345.9M | -18933.6% | -36.9% |
| FY2024 | $37.3M | -$366.3M | -$4.34 | -$144.7M | -1250.4% | -26.2% |
| FY2023 | $371.2M | -$153.6M | -$1.94 | -$269.8M | -60.0% | -12.3% |
| FY2022 | $1.2M | -$650.2M | -$8.36 | -$532.9M | -56190.4% | -37.6% |
| FY2021 | $915.0M | $377.7M | $4.70 | $457.3M | 40.8% | 33.3% |
| FY2020 | $719.0K | -$348.9M | -$5.29 | -$256.7M | -49295.5% | -121.1% |
| FY2019 | $289.6M | $66.9M | $1.17 | $50.0M | 16.1% | 116.9% |
| FY2018 | $3.1M | -$165.0M | -$3.44 | -$99.0M | -5087.8% | -54.8% |
| FY2017 | $41.0M | -$68.4M | -$1.71 | -$77.9M | -157.7% | -30.7% |
| FY2016 | $5.2M | -$23.2M | — | -$55.9M | -1319.3% | -29.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CRISPR Therapeutics AG is facing top-line stagnation, with revenue contracting over the decade.
CRISPR Therapeutics AG has historically struggled to out-earn its cost of capital, averaging just -12.0% ROIC.
CRISPR Therapeutics AG capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CRISPR Therapeutics AG is modeled at -4.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.41 per share.